Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7996119 | 0.96 | GAA (0.53) | GAAGRM4HSD11B1SMN1; SMN2SMO | |
| Cnv2197944 SCHEMBL1429628 | 0.86 | HSD11B1 (0.46) | GAAHSD11B1ALDH1A1TRPV1HDAC3 | |
| SCHEMBL1946173 | 0.83 | GAA (0.53) | GAAGRM4SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL1946390 | 0.82 | ALDH1A1 (0.42) | GAAHSD11B1HTTL3MBTL1KDM4E | |
| Cnv2197944 SCHEMBL12965609 | 0.82 | HSD11B1 (0.48) | GAAHSD11B1ALDH1A1TRPV1 | |
| Cnv2197944 SCHEMBL1429576 | 0.82 | HSD11B1 (0.48) | GAAHSD11B1ALDH1A1TRPV1 | |
| Cnv2197944 SCHEMBL18652790 | 0.82 | HSD11B1 (0.48) | GAAHSD11B1ALDH1A1TRPV1 | |
| Formic Acid SCHEMBL1948929 | 0.82 | L3MBTL1 (0.43) | GAAHSD11B1SMOHTTL3MBTL1 | |
| Cnv2197944 SCHEMBL1429858 | 0.81 | HSD11B1 (0.48) | GAAHSD11B1ALDH1A1TRPV1 | |
| SCHEMBL7997766 | 0.81 | HSD11B1 (0.48) | GAAHSD11B1ALDH1A1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530478-B2 | Piperazine derivatives used as CAV2.2 calcium channel modulators | Convergence Pharmaceuticals Limited (GB) | 2013-09-10 | — | — | US | disclosed |
| EP-2346828-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-2346828-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-06-02 | — | — | US | disclosed |
| WO-2010007072-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CACNA1B, CACNA1C, CACNB2 | GAA 3695/4885GRM4 721/4885HSD11B1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.